Thursday, October 9, 2025

IMF says Bangladesh to receive $1.3 billion under third and fourth reviews

Date:

The International Monetary Fund (IMF) said on Monday (June 23) that Bangladesh will have access to $1.33 billion as the fund has concluded a combined third and fourth review of the country under three facilities.Bangladesh will have immediate access to $884 million under the IMF’s Extended Credit Facility and Extended Fund Facility, and receive another $453 million under the Resilience and Sustainability Facility, the fund said.
IMF also approved an augmentation of 567.2 million special drawing rights or SDRs under its ECF and EFF arrangements with a six-month extension.
Read more: Israel-Iran War LIVE Updates Bangladesh had requested the augmentation in May to address rising external financing needs and support macroeconomic stability. “Bangladesh’s program performance has been broadly satisfactory despite the difficult political and economic context and increased downside risks,” the IMF said in a statement.

The move comes amid persistent macroeconomic pressures, including high inflation, low growth and an external financing gap.

Bangladesh turned to the IMF in 2023 for the $4.7 billion bailout as its foreign reserves were pressured by a global surge in commodity prices triggered by Russia’s invasion of Ukraine, straining its ability to pay for key imports of fuel and gas.

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

Tata Steel faces ₹2,411 crore demand from Odisha authorities for Sukinda mine shortfall

Homegrown steel maker Tata Steel Ltd on Saturday (October...

India’s Earnings Growth Seen Reviving Amid Macro Tailwinds; Financials Turn Positive | Economy News

New Delhi: Driven by favourable policy moves, lower rates,...

Congo to start building gold reserves as price surges, central bank governor says

नवनियुक्त केंद्रीय बैंकर का लक्ष्य सोने का...

Bajaj Healthcare gets CDSCO nod for phase III trials of suvorexant tablets for insomnia

Bajaj Healthcare Ltd on Saturday (October 4) said it...